Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Phylloceuticals has produced its first plant-based PD-1 inhibitor monoclonal antibody only 12 weeks after launching operations in Rapid City, SD.

In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

The presentation included new PK and PD data showing that 90mg of avexitide daily maintained continuous pharmacologic ...

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...

Caribou Biosciences' allogeneic CAR T-cell therapies show promising early efficacy and safety, but require clinical ...

Transmembrane proteins (TPs), also referred to as ‘integral membrane proteins’, make up between 70 % and 80 % of the total ...

A genetically diverse mouse model allowed researchers to identify genes that promote the success of immune checkpoint ...